CA2579768A1 - Enzyme inhibitors and uses thereof - Google Patents

Enzyme inhibitors and uses thereof Download PDF

Info

Publication number
CA2579768A1
CA2579768A1 CA002579768A CA2579768A CA2579768A1 CA 2579768 A1 CA2579768 A1 CA 2579768A1 CA 002579768 A CA002579768 A CA 002579768A CA 2579768 A CA2579768 A CA 2579768A CA 2579768 A1 CA2579768 A1 CA 2579768A1
Authority
CA
Canada
Prior art keywords
optionally substituted
aryl
heteroaryl
hydrogen
10alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002579768A
Other languages
English (en)
French (fr)
Inventor
Siew Yeen Chai
Michael William Parker
Anthony Lloyd Albiston
Craig J. Morton
Hooi Ling Ng
Siying Ye
Frederick A. O. Mendelsohn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Vincents Institute of Medical Research
Florey Institute of Neuroscience and Mental Health
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004905182A external-priority patent/AU2004905182A0/en
Application filed by Individual filed Critical Individual
Publication of CA2579768A1 publication Critical patent/CA2579768A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
CA002579768A 2004-09-09 2005-09-09 Enzyme inhibitors and uses thereof Abandoned CA2579768A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2004905182A AU2004905182A0 (en) 2004-09-09 Enzyme inhibitors and uses thereof
AU2004905182 2004-09-09
PCT/AU2005/001380 WO2006026832A1 (en) 2004-09-09 2005-09-09 Enzyme inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CA2579768A1 true CA2579768A1 (en) 2006-03-16

Family

ID=36036029

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002579768A Abandoned CA2579768A1 (en) 2004-09-09 2005-09-09 Enzyme inhibitors and uses thereof

Country Status (13)

Country Link
US (1) US20080194636A1 (https=)
EP (1) EP1789079B1 (https=)
JP (1) JP5031567B2 (https=)
KR (1) KR20070100878A (https=)
CN (1) CN101039690A (https=)
CA (1) CA2579768A1 (https=)
DK (1) DK1789079T3 (https=)
ES (1) ES2403340T3 (https=)
IL (1) IL181819A (https=)
NZ (1) NZ553688A (https=)
SG (1) SG155901A1 (https=)
WO (1) WO2006026832A1 (https=)
ZA (1) ZA200702041B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009065169A1 (en) 2007-11-19 2009-05-28 Howard Florey Institute Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof
CN101284820B (zh) * 2008-04-25 2011-05-04 南昌大学 一种氨肽酶抑制剂及合成方法
CN103848805A (zh) * 2012-12-06 2014-06-11 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103896900A (zh) * 2012-12-25 2014-07-02 韩冰 一类具有神经保护作用的化合物及其制备方法和用途
MX373831B (es) 2014-05-28 2020-03-25 Astellas Pharma Inc Derivado de piridina.
AR102849A1 (es) 2015-03-09 2017-03-29 Astellas Pharma Inc Compuesto de piridina bicíclica
CA3017028C (en) 2015-07-30 2020-06-16 Monash University Fibrotic treatment
EP4440570A1 (en) 2021-12-01 2024-10-09 Institut National de la Santé et de la Recherche Médicale (INSERM) Irap inhibitors for use in the treatment of inflammatory diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284868A (en) * 1991-10-09 1994-02-08 Eli Lilly And Company Pharmaceutical compounds
US5281619A (en) 1992-09-25 1994-01-25 Eli Lilly And Company Therapy for diabetic complications
EP1004584A3 (en) 1992-11-18 2000-07-05 Eli Lilly And Company Limited Pyranoquinoline derivatives as inhibitors of cell proliferation
US6680332B1 (en) * 1999-06-04 2004-01-20 Euro-Celtique S.A. Substituted 5-oxo-5,6,7,8-tetrahydro-4H-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of AMPA
US7053117B2 (en) * 2001-05-16 2006-05-30 Cytovia, Inc. Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2003011304A1 (en) * 2001-08-02 2003-02-13 Howard Florey Institute Of Experimental Physiology And Medicine Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at4) receptor activity
US20030114418A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor
ES2252656T3 (es) * 2002-02-13 2006-05-16 F. Hoffmann-La Roche Ag Nuevos derivados de piridina y quinolina.
WO2009065169A1 (en) * 2007-11-19 2009-05-28 Howard Florey Institute Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof

Also Published As

Publication number Publication date
IL181819A0 (en) 2007-07-04
EP1789079A4 (en) 2010-09-01
ZA200702041B (en) 2008-09-25
EP1789079B1 (en) 2012-11-07
SG155901A1 (en) 2009-10-29
JP2008512395A (ja) 2008-04-24
DK1789079T3 (da) 2013-03-11
US20080194636A1 (en) 2008-08-14
KR20070100878A (ko) 2007-10-12
WO2006026832A1 (en) 2006-03-16
EP1789079A1 (en) 2007-05-30
ES2403340T3 (es) 2013-05-17
JP5031567B2 (ja) 2012-09-19
CN101039690A (zh) 2007-09-19
NZ553688A (en) 2011-05-27
IL181819A (en) 2013-07-31

Similar Documents

Publication Publication Date Title
US8377963B2 (en) Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
Budygin et al. Correlation between behavior and extracellular dopamine levels in rat striatum: comparison of microdialysis and fast-scan cyclic voltammetry
WO2008046155A1 (en) Methods for regulating glucose homeostasis and agents therefor
Klassen et al. Age-dependent diastolic heart failure in an in vivo Drosophila model
JP7457360B2 (ja) 線維症の処置
EP1789079B1 (en) Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
US12378193B2 (en) Anti-arrhythmicity agents
Yu et al. Nuclear factor of activated T cells 2 is required for osteoclast differentiation and function in vitro but not in vivo
AU2005282229B2 (en) Enzyme inhibitors and uses thereof
DE69626522T2 (de) Peptide mit pronociceptiveigenschaften
Vogel et al. EEG measurements by means of radiotelemetry after intracerebroventricular (ICV) cannulation in rodents
EP3294721A1 (en) 4h-pyran compounds as insulin-regulated aminopeptidase (irap) inhibitors
CN110721307A (zh) 神经调节蛋白1在制备增强trpc6通道活性产品中的应用
Ferraro et al. The new compound GET73, N-[(4-trifluoromethyl) benzyl] 4-methoxybutyramide, Regulates hippocampal Aminoacidergic transmission possibly via an allosteric modulation of mGlu5 receptor. Behavioural evidence of its “anti-alcohol” and anxiolytic properties
AU2007234577A1 (en) Novel compounds and uses thereof
CN111032619A (zh) 金刚烷基甲胺衍生物及其作为药物的用途
US20090010909A1 (en) Novel GPCR and methods of use of the same
Tosini et al. Role of melatonin and dopamine in the regulation of retinal circadian rhythms
Turovskaya et al. Overexpression of BDNF Suppresses the Epileptiform Activity in Cortical Neurons of Heterozygous Mice with a Transcription Factor Sip1 Deletion
CA2611072A1 (en) Novel compounds and uses thereof
Prasad et al. Interaction of USF1/USF2 and α-Pal/Nrf1 to Fmr-1 promoter increases in mouse brain during aging
Zordan et al. The immediate upstream sequence of the mouse Ret gene controls tissue-specific expression in transgenic mice
Swaroop The Dopaminergic Cell-Intrinsic Clock and Bidirectional Relationships of Circadian Disruption and Synucleinopathy
US7872101B1 (en) Modulators of the orphan G protein-coupled receptors GPR78 and GPR26
Ko RGS Proteins in Experimental Parkinsonism and L-Dopa-Induced Dyskinesia

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140909